227 related articles for article (PubMed ID: 3274456)
1. Pretreatment of human renal allografts with monoclonal antibodies to induce long-term tolerance.
Taube D; Welsh KI; Bewick M; Dische FE; Palmer A; Parsons V; Snowden S
Transplant Proc; 1987 Feb; 19(1 Pt 3):1961-3. PubMed ID: 3274456
[No Abstract] [Full Text] [Related]
2. Renal transplantation with cyclosporine in the elderly population.
Velez RL; Brinker KR; Vergne-Marini PJ; Nesser DA; Long DL; Trevino G; Dickerman RM; Helfrich GB
Transplant Proc; 1991 Apr; 23(2):1749-52. PubMed ID: 1905073
[No Abstract] [Full Text] [Related]
3. Use of OKT3 in kidney, pancreas, and liver transplantation.
D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
[No Abstract] [Full Text] [Related]
4. Reversal of steroid- and antithymocyte globulin-resistant acute rejection crises in renal transplantation with monoclonal antibody (OKT3).
Prieto C; Rodriguez-Paternina E; Andrés A; Morales JM; Farias J; Montoyo C; Regueiro JR; Rodicio JL
Transplant Proc; 1990 Aug; 22(4):1753-4. PubMed ID: 2117798
[No Abstract] [Full Text] [Related]
5. Immunosuppression with cyclosporine, azathioprine, and prednisolone in cadaver renal allograft recipients.
Jones RM; Murie JA; Allen R; Jaskowski A; Morris PJ
Transplant Proc; 1987 Feb; 19(1 Pt 3):1926. PubMed ID: 3274453
[No Abstract] [Full Text] [Related]
6. A comparison of three immunosuppressive protocols in patients aged over 50 years.
Fryd DS; So SK; Kruse L; Canafax DM; Sutherland DE; Simmons RL; Najarian JS
Transplant Proc; 1987 Feb; 19(1 Pt 2):1530-1. PubMed ID: 3274374
[No Abstract] [Full Text] [Related]
7. Incidence and impact of acute rejection episodes on short- and long-term graft survival in recipients of simultaneous pancreas-kidney transplantation.
Cantarovich D; Giral M; Josien R; Karam G; Hourmant M; Dantal J; Blancho G; Soulillou JP
Transplant Proc; 1995 Feb; 27(1):1319. PubMed ID: 7878897
[No Abstract] [Full Text] [Related]
8. Effective induction immunosuppression for cadaver renal transplantation at the St. Francis Regional Medical Center.
Shield CF
Clin Transpl; 1990; ():265-74. PubMed ID: 2129408
[TBL] [Abstract][Full Text] [Related]
9. Cox regression analysis of outcome risk factors in 519 renal allograft recipients.
Canafax DM; Savik SK; Draxler CA; Le CT; Ascher NL; Payne WD; Sutherland DE; Migliori RJ; Simmons RL; Najarian JS
Transplant Proc; 1987 Feb; 19(1 Pt 3):1947-8. PubMed ID: 3274455
[No Abstract] [Full Text] [Related]
10. Quadruple drug induction treatment in patients with ATN-kidneys: expensive but effective.
Schilling M; Schleibner S; Abendroth D; Illner WD; Schneeberger H; Land W
Transplant Proc; 1990 Oct; 22(5):2283. PubMed ID: 2219369
[No Abstract] [Full Text] [Related]
11. Contribution of T-cell subset monitoring of renal transplant recipients in the cyclosporine era.
Khanuja PS; Toledo-Pereyra LH; Gordon DA; Bandlien KO; Whitten JI
Transplant Proc; 1989 Feb; 21(1 Pt 2):1852-3. PubMed ID: 2652602
[No Abstract] [Full Text] [Related]
12. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation.
Steininger R; Mühlbacher F; Hamilton G; Längle F; Gnant M; Popow T; Sautner T; Götzinger P; Wamser P; Stockenhuber F
Transplant Proc; 1991 Aug; 23(4):2269-71. PubMed ID: 1908154
[No Abstract] [Full Text] [Related]
13. Triple immunosuppressive therapy in immunologic high-risk renal allograft recipients.
Cole E; Robinson C; Bear R
Transplant Proc; 1989 Feb; 21(1 Pt 2):2026-7. PubMed ID: 2652662
[No Abstract] [Full Text] [Related]
14. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
Friend PJ; Rebello P; Oliveira D; Manna V; Cobbold SP; Hale G; Jamieson NV; Jamieson I; Calne RY; Harris DT
Transplant Proc; 1995 Feb; 27(1):869-70. PubMed ID: 7879212
[No Abstract] [Full Text] [Related]
15. Single center randomized trial using ATG v OKT3 treatment in steroid resistant rejection crises after kidney transplantation.
Blümke M; Kirste G; Wanner U; Wilms H
Transplant Proc; 1989 Feb; 21(1 Pt 2):1747. PubMed ID: 2652571
[No Abstract] [Full Text] [Related]
16. Quadruple-drug induction therapy in combined renal and pancreatic transplantation--OKT3 versus ATG.
Illner WD; Theodorakis J; Abendroth D; Schleibner S; Stangl M; Landgraf R; Land W
Transplant Proc; 1990 Aug; 22(4):1586-7. PubMed ID: 2117795
[No Abstract] [Full Text] [Related]
17. The use of OKT3 in combined pancreas-kidney allotransplantation.
Melzer JS; D'Alessandro AM; Kalayoglu M; Pirsch JD; Belzer FO; Sollinger HW
Transplant Proc; 1990 Apr; 22(2):634-5. PubMed ID: 2183431
[No Abstract] [Full Text] [Related]
18. Effective prevention of interstitial rejection crises in immunological high risk patients following renal transplantation: use of high doses of the new monoclonal antibody BMA 031.
Dendorfer U; Hillebrand G; Kasper C; Smely S; Weschka M; Hammer C; Racenberg J; Gurland HJ; Land W
Transplant Proc; 1990 Aug; 22(4):1789-90. PubMed ID: 2389450
[No Abstract] [Full Text] [Related]
19. Increased frequency of kidney allograft rejection in recipients with cyclosporine and/or steroid-resistant lymphoid responses.
Bowes LG; Dumble LJ; Francis DM; Macdonald IM; Clunie GJ; Kincaid-Smith P
Transplant Proc; 1990 Oct; 22(5):2139-40. PubMed ID: 2145672
[No Abstract] [Full Text] [Related]
20. The role of antilymphocyte globulin in cadaver renal transplantation.
Novick AC
Transplant Proc; 1986 Jun; 18(3 Suppl 2):22-7. PubMed ID: 3521000
[No Abstract] [Full Text] [Related]
[Next] [New Search]
